Stock Events

Stock Events

Precision Biosciences 

$8.60
45
+$0.10+1.18% 09:19 Today

Statistics

Day High
8.54
Day Low
8.49
52W High
9.62
52W Low
3.53
Volume
16,254
Avg. Volume
-
Mkt Cap
234.61M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.25
-1.72
-1.19
-0.66
Expected EPS
-0.844
Actual EPS
N/A

Financials

-133.45%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
34.26MRevenue
-45.72MNet Income

Analyst Ratings

36.67Average Price Target
The highest estimate is 60.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DTIL. It's not an investment recommendation.
Amazon
14
AMZN
Microsoft
11
MSFT
NVIDIA
11
NVDA
Tesla
10
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is a leading company in the gene editing space, directly competing with Precision Biosciences' ARCUS genome editing platform.
Editas Medicine
EDIT
Mkt Cap433.1M
Editas Medicine operates in the genome editing field, utilizing CRISPR technology which competes with Precision Biosciences' gene editing approaches.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is another key player in CRISPR/Cas9 technology, offering direct competition to Precision Biosciences' genome editing solutions.
Beam Therapeutics
BEAM
Mkt Cap2.76B
Beam Therapeutics competes with Precision Biosciences through its base editing technology, a novel form of genome editing.
Allogene Therapeutics
ALLO
Mkt Cap708.26M
Allogene Therapeutics is involved in the development of allogeneic CAR T cell therapies, competing with Precision Biosciences' CAR T programs.
Adaptive Biotechnologies
ADPT
Mkt Cap3.94B
Adaptive Biotechnologies competes in the broader genomic medicine space, offering technologies that could be seen as complementary or competitive to Precision Biosciences' platforms.
Fate Therapeutics
FATE
Mkt Cap307.94M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies, competing with Precision Biosciences' cell therapy approaches.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space, particularly in CAR T therapies, which is a focus area for Precision Biosciences.

About

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Show more...
CEO
Michael Amoroso
Employees
67
Country
United States
ISIN
US74019P2074
WKN
000A400AS

Listings

MU
DE
PBS.MU
STU
DE
PBS0.STU
F
DE
PBS0.F
MU
DE
PBS0.MU

0 Comments

Share your thoughts

FAQ

What is Precision Biosciences stock price today?▼
The current price of DTIL is $8.60 USD — it has increased by +1.18% in the past 24 hours. Watch Precision Biosciences stock price performance more closely on the chart.
What is Precision Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Precision Biosciences stocks are traded under the ticker DTIL.
Is Precision Biosciences stock price growing?▼
DTIL stock has risen by +16.44% compared to the previous week, the month change is a +15.49% rise, over the last year Precision Biosciences has showed a +82.4% increase.
What is Precision Biosciences market cap?▼
Today Precision Biosciences has the market capitalization of 234.61M
When is the next Precision Biosciences earnings date?▼
Precision Biosciences is going to release the next earnings report on November 10, 2026.
What were Precision Biosciences earnings last quarter?▼
DTIL earnings for the last quarter are -1.26 USD per share, whereas the estimation was -0.8 USD resulting in a -56.72% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Precision Biosciences revenue for the last year?▼
Precision Biosciences revenue for the last year amounts to 34.26M USD.
What is Precision Biosciences net income for the last year?▼
DTIL net income for the last year is -45.72M USD.
How many employees does Precision Biosciences have?▼
As of August 20, 2026, the company has 67 employees.
In which sector is Precision Biosciences located?▼
Precision Biosciences operates in the Health & Wellness sector.
When did Precision Biosciences complete a stock split?▼
The last stock split for Precision Biosciences was on February 14, 2024 with a ratio of 1:30.
Where is Precision Biosciences headquartered?▼
Precision Biosciences is headquartered in DURHAM, United States.